STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA ...
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms ...
STORM Therapeutics, a Cambridge-based clinical stage company targeting RNA modifications to reprogram cells and develop novel ...
Storm Therapeutics raises $56M in Series C funding to accelerate cancer therapy development and expand its innovative ...
Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31 Patients ...
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
This important paper substantially advances our understanding of how Molidustat may work, beyond its canonical role, by identifying its therapeutic targets in cancer. This study presents a compelling ...
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable ...
Building on validated HIP technology, Sana Biotechnology is advancing SC451, a stem cell-derived therapy designed as a one-time treatment targeting normal blood glucose without exogenous insulin or ...
Columnist Dr Henar Hevia, J&J Innovative Medicine, explores why oncology’s future hinges not on new treatments, but on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results